Latest Tax Incentives News

Rare Foods Australia has secured shareholder approval to voluntarily delist from the ASX, while implementing significant cost reductions and achieving record growth in its Subsea Estate wine brand.

Mount Burgess Mining reports encouraging hydrometallurgical test results from its Nxuu polymetallic deposit, achieving high recoveries for zinc, vanadium, and rare earth elements. The company also completed a modest capital raise to support ongoing project development.

South Harz Potash Limited has progressed its Ohmgebirge project with key steps including advancing the Sollstedt mine acquisition, securing A$500,000 in new equity, and pursuing strategic funding avenues such as German R&D rebates and European Union grants.

InteliCare Holdings reported a net operating cash outflow of AUD 447,000 for Q1 2025 but remains confident in sustaining operations through active cash management and potential capital raises.

Heavy Rare Earths Limited (ASX:HRE) has expanded its uranium exploration footprint through a significant asset acquisition in South Australia and advanced geophysical surveys, positioning itself for targeted drilling in 2025.

Cobalt Blue Holdings progresses its Kwinana Cobalt Refinery towards a Final Investment Decision while expanding into copper and base metals through the Halls Creek Project. The cobalt market faces a structural shift amid DRC export restrictions, supporting a strategic corporate rebrand and leadership changes.

Cann Group Limited reported a 20% rise in Q3 production and improved operating cash flow, while navigating a 38% sales dip due to order timing. The company bolstered its balance sheet with new funding and expanded its Botanitech distribution network.

Propell Holdings reports Q3 FY25 cash outflows alongside a strategic shift with a new ‘Low Doc’ credit model and confirms its upcoming ASX delisting.

Acrux Limited reports strong momentum from recent topical pharmaceutical launches, driving a significant uptick in profit share income expected in the coming quarter. The company also secured nearly $4 million through a placement and share purchase plan, alongside a $1.73 million R&D-backed loan.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.